Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Recruiting 5Completed 4Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × RAD1901 × Clear all
NCT05963997 2026-03-23

SUMIT-ELA

Carrick Therapeutics Limited

Phase 1/2 Completed
49 enrolled
Breast

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed
478 enrolled 16 charts 1 FDA
Breast

Breast Neoplasms

NCT06126575 2024-11-19

A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

Stemline Therapeutics, Inc.

Phase 1 Completed
16 enrolled
Breast

Breast Neoplasms

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
16 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡